ASH 2022 Conference Coverage

 

Benign Hematology
05:00

ASH 2022 Conference Coverage

Cognitive Impairment in Patients With ITP

FEATURING Camelia Vladescu
  • 76 views
  • January 28, 2023
37:56

ASH 2022 Conference Coverage

Updates on Thrombosis & COVID-19

FEATURING Beverley Hunt
  • 48 views
  • January 18, 2023
16:56

ASH 2022 Conference Coverage

ASH 2022: What's Hot in Sickle Cell Disease Research 2022

FEATURING Elizabeth Klings
  • 336 views
  • January 11, 2023
  • 4
08:41

ASH 2022 Conference Coverage

ASH 2022 Long-Term Outcomes of Patients With TDT Followed Up to 8 Years Post-Treatment With Betibeglogene Autotemcel Gene Therapy and Predictors of Successful Treatment Outcomes in Phase 3 Trials

FEATURING Mark Walters
  • 99 views
  • January 5, 2023
06:01

ASH 2022 Conference Coverage

ASH 2022: Mitapivat Improves Iron Overload in Patients With Pyruvate Kinase Deficiency

FEATURING Kevin Kuo
  • 84 views
  • January 4, 2023
  • 1
05:42

ASH 2022 Conference Coverage

ASH 2022 Health-Related QOL in Patients With Hemophilia A or B With Inhibitors on Concizumab Prophylaxis: Results From the Phase 3 explorer7 Study

FEATURING Amy Shapiro
  • 88 views
  • December 28, 2022
  • 2
11:26

ASH 2022 Conference Coverage

ASH 2022 Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial ADVANCE IV: Efficacy & Safety of IV Efgartigimod in Adults With Primary ITP

FEATURING Catherine Broome
  • 85 views
  • December 22, 2022
11:03

ASH 2022 Conference Coverage

ASH 2022 Low-Molecular-Weight Heparin vs. Standard Pregnancy Care for Women With Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial

FEATURING Saskia Middeldorp
  • 440 views
  • December 22, 2022
  • 3
21:11

ASH 2022 Conference Coverage

ASH 2022: Immune Response to SARS-CoV-2 and Vaccination

FEATURING Shane Crotty
  • 1,476 views
  • December 22, 2022
  • 7
07:35

ASH 2022 Conference Coverage

ASH 2022 Hydroxyurea Dosing in Very Young Children With Sickle Cell Anemia (HUGKISS): A Multicenter, Randomized, Controlled Trial

FEATURING Winfred Wang
  • 75 views
  • December 21, 2022
  • 1
10:53

ASH 2022 Conference Coverage

ASH 2022 New Biological Insights on Clonal Evolution in Aplastic Anemia in the Eltrombopag Era

FEATURING Austin Kulasekararaj
  • 97 views
  • December 21, 2022
  • 2
09:20

ASH 2022 Conference Coverage

ASH 2022 Phase III APPLY-PNH Study: Oral Monotherapy With Iptacopan Has Superior Efficacy to SoC Eculizumab/Ravulizumab & Favorable Safety in Pts With PNH and Residual Anemia

FEATURING Regis de Latour
  • 130 views
  • December 20, 2022
24:02

ASH 2022 Conference Coverage

ASH 2022 Controversies in the Prevention of VTE for Medical Inpatients: To Prophylax or Not and How Much and How Long

FEATURING Alex Spyropoulos
  • 141 views
  • December 16, 2022
  • 2
04:37

ASH 2022 Conference Coverage

ASH 2022 Outcomes of Older Patients With Aplastic Anemia Treated With Frontline Anti-Thymocyte Globulin-Based Immunosuppressive Therapy

FEATURING Jajastu Senapati
  • 71 views
  • December 16, 2022
12:56

ASH 2022 Conference Coverage

ASH 2022 Lentiviral-Mediated Gene Therapy for Adults and Children With Severe PK Deficiency: Results From an Ongoing Global Phase 1 Study

FEATURING Ami Shah
  • 70 views
  • December 16, 2022